Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses-Reference-Cited by-同舟云学术

Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses

Published:2012-03 Issue:2 Volume:1 Page:109-111
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Rassen Jeremy A¹,Schneeweiss Sebastian¹

Affiliation:

1. Division of Pharmacoepidemiology & Pharmacoeconomics, Department of Medicine, Brigham & Women’s Hospital & Harvard Medical School, Boston, MA, USA.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer.12.12

Reference10 articles.

1. Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States

2. Developments in Post-marketing Comparative Effectiveness Research

3. Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development

4. Simulation of Clinical Trials

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib for the Treatment of HR+HER2− Metastatic Breast Cancer: An Institutional Experience;Cancers;2024-05-10

2. Overlap, matching, or entropy weights: what are we weighting for?;Communications in Statistics - Simulation and Computation;2024-02-29

3. Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice;Drugs - Real World Outcomes;2023-09-29

4. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan;Breast Cancer;2023-05-22

5. Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib;Drugs - Real World Outcomes;2022-09-12